IMUX Insider Trading Activity and SEC Form 4 Filings
IMUX insider trading summary
No open-market insider purchases or sales of Immunic, Inc. (IMUX) have been reported on SEC Form 4 in the past 12 months.
Latest IMUX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 13, 2025 | Duane Nash | Executive Chairman | Buy | $17K (20,000 @ $0.83) |
| Jun 5, 2025 | Joerg Neermann | Director | Buy | $23K (30,000 @ $0.76) |
| Jun 5, 2025 | Jason Tardio | President and COO | Buy | $10K (12,512 @ $0.79) |
| Jun 4, 2025 | Daniel Vitt | CEO and Director | Buy | $12K (15,000 @ $0.77) |
| Jun 4, 2025 | Joerg Neermann | Director | Buy | $54K (70,000 @ $0.77) |
| Jun 3, 2025 | Glenn Whaley | Chief Financial Officer | Buy | $32K (45,000 @ $0.71) |
| Jun 3, 2025 | Richard Alan Rudick | Director | Buy | $100K (143,075 @ $0.70) |
| Nov 12, 2024 | Richard Alan Rudick | Director | Buy | $100K (87,300 @ $1.15) |
| Feb 26, 2024 | Daniel Vitt | President and CEO | Buy | $18K (14,000 @ $1.31) |
| May 15, 2023 | Glenn Whaley | Chief Financial Officer | Buy | $9K (5,000 @ $1.75) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.